CCEL
Cryo-Cell International, Inc.
Medical - Care Facilities
Market Cap$28M
5Y Perf.-53.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CCEL vs NTRA vs FATE vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$31.16B
5Y Perf.+401.3%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-92.5%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.+23.2%
CCEL vs NTRA vs FATE vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CCEL | NTRA | FATE | BEAM |
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Diagnostics & Research | Biotechnology | Biotechnology |
| Market Cap | $28M | $31.16B | $280M | $3.23B |
| Revenue (TTM) | $32M | $2.31B | $7M | $132M |
| Net Income (TTM) | $400K | $-208M | $-136M | $-65M |
| Gross Margin | 77.1% | 64.8% | — | -64.2% |
| Operating Margin | 13.6% | -13.4% | -22.2% | -281.0% |
| Forward P/E | 69.0x | — | — | — |
| Total Debt | $13M | $214M | $78M | $294M |
| Cash & Equiv. | $561K | $1.08B | $47M | $295M |
CCEL vs NTRA vs FATE vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CCEL
NTRA
FATE
BEAM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | 100 | 46.6 | -53.4% |
| Natera, Inc. (NTRA) | 100 | 501.3 | +401.3% |
| Fate Therapeutics, … (FATE) | 100 | 7.5 | -92.5% |
| Beam Therapeutics I… (BEAM) | 100 | 123.2 | +23.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCEL vs NTRA vs FATE vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CCEL leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Fate Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. BEAM also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CCEL
Cryo-Cell International, Inc.
The Income Pick
CCEL carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 0.35, yield 7.1%
- Better valuation composite
- 1.3% margin vs FATE's -20.5%
- Beta 0.35 vs FATE's 2.17
Best for: income & stability
NTRA
Natera, Inc.
The Long-Run Compounder
NTRA is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 20.9% 10Y total return vs BEAM's 67.8%
- Lower volatility, beta 1.26, Low D/E 12.5%, current ratio 3.39x
Best for: long-term compounding and sleep-well-at-night
FATE
Fate Therapeutics, Inc.
The Momentum Pick
FATE is the #2 pick in this set and the best alternative if momentum is your priority.
- +143.0% vs CCEL's -26.1%
Best for: momentum
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the clearest fit if your priority is growth exposure and defensive.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- Beta 2.14, current ratio 13.09x
- 120.0% revenue growth vs FATE's -51.2%
Best for: growth exposure and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs FATE's -51.2% |
| Value | CCEL | Better valuation composite |
| Quality / Margins | CCEL | 1.3% margin vs FATE's -20.5% |
| Stability / Safety | CCEL | Beta 0.35 vs FATE's 2.17 |
| Dividends | CCEL | 7.1% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | FATE | +143.0% vs CCEL's -26.1% |
| Efficiency (ROA) | CCEL | 0.6% ROA vs FATE's -42.7% |
CCEL vs NTRA vs FATE vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2023
Segment breakdown not available.
CCEL vs NTRA vs FATE vs BEAM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCCELLAGGINGBEAM
Who Leads Where
CCEL leads in 3 of 6 categories
NTRA leads 1 • FATE leads 0 • BEAM leads 0 • 1 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
FATEFate Therapeutics, In…
0leads
NTRANatera, Inc.
1leads
CCELCryo-Cell Internation…
3leads
6 Total Categories
CATEGORYLEADERvs NTRAvs FATEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CCEL4/6
Valuation MetricsMultiples, price ratios, and targets
CCEL2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CCEL5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CCEL leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.3B annually — 347.0x FATE's $7M. CCEL is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to FATE's -20.5%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $32M | $2.3B | $7M | $132M |
| EBITDAEarnings before interest/tax | $6M | -$310M | -$148M | -$355M |
| Net IncomeAfter-tax profit | $399,609 | -$208M | -$136M | -$65M |
| Free Cash FlowCash after capex | $6M | $97M | -$88M | -$384M |
| Gross MarginGross profit ÷ Revenue | +77.1% | +64.8% | — | -64.2% |
| Operating MarginEBIT ÷ Revenue | +13.6% | -13.4% | -22.2% | -2.8% |
| Net MarginNet income ÷ Revenue | +1.3% | -9.0% | -20.5% | -49.2% |
| FCF MarginFCF ÷ Revenue | +19.1% | +4.2% | -13.2% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.0% | +39.8% | -26.4% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.8% | +185.4% | +38.6% | +26.6% |
CCEL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
CCEL leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $28M | $31.2B | $280M | $3.2B |
| Enterprise ValueMkt cap + debt − cash | $40M | $30.3B | $312M | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | 69.00x | -144.62x | -2.11x | -38.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 10.13x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.87x | 13.51x | 42.18x | 23.14x |
| Price / BookPrice ÷ Book value/share | — | 17.55x | 1.39x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 7.70x | 285.53x | — | — |
CCEL leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
CCEL leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
BEAM delivers a -5.9% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-66 for FATE. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to FATE's 0.38x. On the Piotroski fundamental quality scale (0–9), CCEL scores 7/9 vs FATE's 2/9, reflecting strong financial health.
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -15.3% | -65.8% | -5.9% |
| ROA (TTM)Return on assets | +0.6% | -10.6% | -42.7% | -4.6% |
| ROICReturn on invested capital | — | -36.1% | -36.5% | -31.1% |
| ROCEReturn on capital employed | +8.3% | -18.3% | -43.1% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x | 0.38x | 0.24x |
| Net DebtTotal debt minus cash | $12M | -$862M | $31M | -$1M |
| Cash & Equiv.Liquid assets | $560,960 | $1.1B | $47M | $295M |
| Total DebtShort + long-term debt | $13M | $214M | $78M | $294M |
| Interest CoverageEBIT ÷ Interest expense | 1.62x | -25.21x | — | 1.08x |
CCEL leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $318 for FATE. Over the past 12 months, FATE leads with a +143.0% total return vs CCEL's -26.1%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs FATE's -23.6% — a key indicator of consistent wealth creation.
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +0.6% | -3.9% | +145.5% | +16.0% |
| 1-Year ReturnPast 12 months | -26.1% | +37.3% | +143.0% | +93.9% |
| 3-Year ReturnCumulative with dividends | -15.5% | +314.0% | -55.4% | -5.6% |
| 5-Year ReturnCumulative with dividends | -41.2% | +115.9% | -96.8% | -55.6% |
| 10-Year ReturnCumulative with dividends | +61.3% | +2089.4% | +40.5% | +67.8% |
| CAGR (3Y)Annualised 3-year return | -5.4% | +60.6% | -23.6% | -1.9% |
NTRA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CCEL and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCEL is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than FATE's 2.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs CCEL's 54.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 1.26x | 2.17x | 2.14x |
| 52-Week HighHighest price in past year | $6.35 | $256.36 | $2.46 | $36.44 |
| 52-Week LowLowest price in past year | $2.72 | $131.81 | $0.91 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +54.3% | +85.7% | +98.6% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 49.9 | 57.1 | 81.0 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 12K | 1.3M | 1.9M | 2.0M |
Evenly matched — CCEL and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NTRA as "Buy", FATE as "Buy", BEAM as "Buy". Consensus price targets imply 1525.5% upside for FATE (target: $40) vs 19.4% for NTRA (target: $263). CCEL is the only dividend payer here at 7.13% yield — a key consideration for income-focused portfolios.
| Metric | CCELCryo-Cell Interna… | NTRANatera, Inc. | FATEFate Therapeutics… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $262.50 | $39.50 | $40.83 |
| # AnalystsCovering analysts | — | 27 | 31 | 27 |
| Dividend YieldAnnual dividend ÷ price | +7.1% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | $0.25 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.1% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CCEL leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). NTRA leads in 1 (Total Returns). 1 tied.
Best OverallCryo-Cell International, In… (CCEL)Leads 3 of 6 categories
Loading custom metrics...
CCEL vs NTRA vs FATE vs BEAM: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is CCEL or NTRA or FATE or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Cryo-Cell International, Inc. (CCEL) offers the better valuation at 69. 0x trailing P/E, making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCEL or NTRA or FATE or BEAM?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus FATE's +40. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCEL or NTRA or FATE or BEAM?
By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.
(CCEL) is the lower-risk stock at 0. 35β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 518% more volatile than CCEL relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CCEL or NTRA or FATE or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCEL or NTRA or FATE or BEAM?
Cryo-Cell International, Inc.
(CCEL) is the more profitable company, earning 1. 3% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 1. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10. 9% versus -22. 2% for FATE. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CCEL or NTRA or FATE or BEAM?
In this comparison, CCEL (7.
1% yield) pays a dividend. NTRA, FATE, BEAM do not pay a meaningful dividend and should not be held primarily for income.
07Is CCEL or NTRA or FATE or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Cryo-Cell International, Inc.
(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 7. 1% yield). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCEL: +61. 3%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CCEL and NTRA and FATE and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CCEL is a small-cap income-oriented stock; NTRA is a mid-cap high-growth stock; FATE is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock. CCEL pays a dividend while NTRA, FATE, BEAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(CCEL: -3.0% · NTRA: 39.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.